"I was surprised by how many people who were depressed also had chronic pain," says the study's lead author, Alan Schatzberg, M.D., a professor of psychiatry and behavioral sciences at Stanford.

He treated 19,000 patients over the course of more than thirty years.

"It's not some kind of sweep-under-the-rug thing.

While there are other biotech companies working with cannabis, Oxis International has focused in with their definitive licensing agreement for treatment of multiple myeloma.

There are limitations to this approach.